StockIQpro
NASDAQ:PACB

Pacific Biosciences of California, Inc.

Track all markets on TradingView
Track all markets on TradingView

Pacific Biosciences of California, Inc.'s revenue grew 3.9% in fiscal 2025 to $160.0M while operating margin fell to −346.2%, its lowest in 10 years. Free cash flow was −$113.9M, −71.2% of revenue, and the diluted share count rose 4.0%.Summary generated from Pacific Biosciences of California, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$160.0M
Revenue growth+3.9%
Revenue, 5-yr CAGR+15.2%
Gross margin28.6%
Operating margin−346.2%
Net margin−341.5%
ROICn/a
Return on equity−213.5%
Debt / equityn/a
Free cash flow−$113.9M
FCF margin−71.2%
Share count change+4.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue131128201154160
Operating income−210−307−334−474−554
Net income−181−314−307−310−546
Free cash flow−117−280−268−212−114

Recent filings

From SEC EDGAR

Peers

Laboratory analytical instruments